Amgen Inc.

Other

Xencor, Inc.

Ucb Pharma, S.a.

Ucb S.a.

Kevin Graham

Neeraj Jagdish Agrawal

Christopher Mohr

Aaron George Winters

Kenneth William Walker

Agnes Eva Hamburger

Derek Evan Piper

Zhulun Wang

Cen Xu

John A Latham

Li Zhang

Wenyan Shen

David Guenther Winkler

Hsieng Sen Lu

Mei-Mei Tsai

Martyn Kim Robinson

Alastair Lawson

Christopher J Paszty

Alistair James Henry

Xueming Qian

Grant Shimamoto

Andy Popplewell

Barbara S Tipton

Gregory L Moore

Jonathan Daniel Oliner

Jennitte LeAnn Stevens

Christopher Murawsky

Benjamin M Alba

Dante Romanini

Olivier Nolan-Stevaux

Oliver Thiel

Kelly Sue Warmington

Mark Pound

Kelly Sue Hoffmann

Cong Li

Alex W Jacobitz

Ray Lieh Yoon Low

Victoria Wagner

Stephen Smith

John K Kawooya

Kelly Sue Hoffman

Marty Kim Robinson

John Latham

The present invention is directed to a CH3-containing molecule comprising (a) a first polypeptide comprising a CH3 domain and a negatively charged domain comprising consecutive negatively charged amino acid residues; and (b) a second polypeptide comprising a CH3 domain and a positively charged domain comprising consecutive positively charged amino acid residues. Also provided are methods for conjugating synthetic molecules to a multi-specific antigen binding molecule.

Bispecific antibodies with cleavable C-terminal charge-paired tags

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof

The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.

Anti-STEAP1 antigen-binding protein

Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof

PAC1 antibodies and uses thereof

A modular trailer system is described, wherein a gooseneck, deck, and dolly are attachable to each other in a variety of ways. One configuration allows the gooseneck and dolly to be attached to either end of the deck. Another configuration allows the gooseneck and dolly to be attached directly to each other. This permits the method of transporting a deck to a site, and then returning the gooseneck and dolly to another location.

Modular trailer system and method

Embodiments of systems, methods and computer program products are described for implementing repository relationship programming. Implementations described herein describe processes for implementing a union of concerns, integrating concerns, assembling concerns and separating concerns.

Repository relationship programming

The present invention relates to binding agents for WISE, and includes for their manufacture and use.

Wise binding agents and epitopes

Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.

Sclerostin-binding antibodies

A gel that includes a fungicide or an anti-bacterial is contained within a single dosage packet that includes a tapered nozzle end and a body. The fungicide or anti-bacterial gel is applied to the hoof of a horse by opening the packet at the tapered nozzle end and squeezing the body. The gel is then spread over the frog and sole of the hoof with a portion of the packet. The gel is heated so that it spreads to recessed areas of the hoof that can contain the bacterial and fungus infections.

System and method for applying medication to a hoof

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.

Angiopoietin-2 specific binding agents

Sclerostin-binding antibody

Growing community of inventors

Thousand Oaks, CA, United States of America

Kevin Graham